Lenalidomide-Associated Immune Thrombocytopenia: A Case Report and Review of the Literature by William Forehand III, Germame Ajebo, Michael Toscano, Anand Jillella, Paul Dainer

“…More recently, it has been introduced for use in treating other hematologic malignancies. Although the drug is known to cause myelosuppression, there have been rare reports of lenalidomide-associated immune thrombocytopenia (ITP). …”
Get full text

An Unusual Presentation of Tumor Lysis Syndrome in a Patient with Advanced Gastric Adenocarcinoma: Case Report and Literature Review by Danica Maria Vodopivec, Jose Enrique Rubio, Alessia Fornoni, Oliver Lenz

“…TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. …”
Get full text

Sintilimab for treating progressive multifocal leukoencephalopathy caused by human polyomavirus 2 virus infection following allogeneic hematopoietic cell transplantation: a case re... by Xuelian Jin, Xushu Zhong, Qinyu Liu, Xinchuan Chen

“…No graft-versus-host disease occurred, but manageable immune reconstitution inflammatory syndrome was observed.Conclusion: Sintilimab, a PD-1 inhibitor, might be used to treat PML in patients with hematologic malignancies undergoing allo-HSCT, which needs further investigation.…”
Get full text

Machine learning identifies the association between second primary malignancies and postoperative radiotherapy in young-onset breast cancer patients. by Yulin Lai, Peiyuan Huang

“…YWBC patients receiving PORT had significantly greater risks of second primary solid malignancies (SPSMs, RR = 1.61), including breast cancer (RR = 1.89), lung cancer (RR = 2.12) and thyroid cancer (RR = 1.48), but not second primary hematologic malignancies (RR = 1.32; 0.94-1.88). SPSMs were more common in YWBC individuals who were black, had a lower median household income and had fewer lymph nodes examined. …”
Get full text

Targeting BCMA in multiple myeloma: designs, challenges, and future directions by Yi Hu, Yuetao Xie, Xiaodong Wang, Lufeng Yang, He Geng, Zugang Yi, Yao Zhang, Lin Ma, Fang Chen

“…By detailing both the breakthroughs and ongoing challenges in BCMA CAR T cell therapy, this review offers a comprehensive perspective on the current state and future possibilities of CAR T cell therapy for MM and its expanding role in treating hematologic malignancies and beyond.…”
Get full text

STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes by Zoe King, Sudhamsh Reddy Desai, David A. Frank, Aditi Shastri

“…By integrating findings from recent preclinical and clinical studies, this review provides insights into the evolving landscape of STAT-targeted therapies, highlighting the promise of these approaches in enhancing treatment efficacy and improving patient outcomes in high-risk hematologic malignancies.…”
Get full text

Novel gene manipulation approaches to unlock the existing bottlenecks of CAR-NK cell therapy by Fatemeh Dehghan, Yekta Metanat, Mandana Askarizadeh, Ehsan Ahmadi, Vahid Moradi

“…Currently, CAR-T cell therapy is known as an efficacious treatment for patients with relapsed/refractory hematologic malignancies. Nonetheless, this method faces several bottlenecks, including low efficacy for solid tumors, lethal adverse effects, high cost of autologous products, and the risk of GvHD in allogeneic settings. …”
Get full text

Enhancing precision in cancer treatment: the role of gene therapy and immune modulation in oncology by Emile Youssef, Brandon Fletcher, Dannelle Palmer

“…This review highlights innovative therapeutic strategies, including gene replacement, gene silencing, oncolytic virotherapy, CAR-T cell therapy, and CRISPR-Cas9 gene editing, with a focus on their application in both hematologic malignancies and solid tumors. CRISPR-Cas9, a revolutionary tool in precision medicine, enables precise editing of cancer-driving mutations, enhancing immune responses and disrupting tumor growth mechanisms. …”
Get full text

Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects by Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci, Matt Coffey, Gerard Nuovo, Douglas W. Sborov, Flavia Pichiorri, Craig C Hofmeister

Get full text

Comparative Effectiveness of Remestemcel-L-rknd versus Ruxolitinib in Pediatric Patients with Steroid-Refractory Acute Graft-Versus-Host Disease using Simulated Treatment Compariso... by Gabriel Tremblay, Dimitrios Tomaras, Eric Strati, Anna Forsythe

“…**Background:** Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be a lifesaving treatment for hematologic malignancies, but acute graft-versus-host-disease (aGVHD) is a potentially deadly adverse effect experienced by up to half of allo-HSCT recipients. …”
Get full text

Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/β-Catenin Complex and Associated Genetic Alterations by Maria Del Valle Estopinal, Lavinia P. Middleton, Bita Esmaeli, Keyur P. Patel, Sara Nowroozizadeh, Michelle D. Williams

Get full text

Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer by Lijuan Qin, Yuan Li, Juan Liu, Xiaoqin An

“…Among the most promising approaches are cellular therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapy, which has shown remarkable success in hematologic malignancies. However, the application of these therapies to solid tumors, such as lung and colorectal cancers, has faced significant challenges. …”
Get full text

Malignant Phyllodes Tumor and Acute Megakaryoblastic Leukemia Sharing a Common Clonal Origin by Yngvar Fløisand, Klaus Beiske, Geir Erland Tjønnfjord, Dag Heldal, Bodil Bjerkehagen, Mona-Elisabeth Revheim, Sverre Heim, Øyvind Sverre Bruland, Kirsten Sundby Hall, Anne Tierens, Jan Delabie

“…There is a well-known association in male patients between mediastinal germ cell tumors (GCT) and hematologic malignancies, with a propensity towards acute megakaryoblastic leukemia. …”
Get full text

Immunotherapy-associated autoimmune hemolytic anemia by Uqba Khan, Tarik Hadid, Farman Ali, Muhammad Siddique Khurram, Awais Zaka

“…Background Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have been the forefront of cancer immunotherapy in recent years. …”
Get full text

Comparative Study of Regulatory T Cell Function of Human CD25+CD4+ T Cells from Thymocytes, Cord Blood, and Adult Peripheral Blood by Wakae Fujimaki, Nozomu Takahashi, Kei Ohnuma, Masayoshi Nagatsu, Hiromi Kurosawa, Satoko Yoshida, Nam H. Dang, Takehiko Uchiyama, Chikao Morimoto

Get full text

T-Cell Large Granular Lymphocytic Leukemia with Extremely Rare Immunophenotype (CD4/CD8 Double-Positive) Followed by Multiple Myeloma Diagnosis by Dina Soliman, Sherin Sallam, Susanna Akiki, Deena Mudawi, Feryal Ibrahim

“…T-LGLL has been associated with reactive conditions such as autoimmune diseases and viral infections and has also been reported in association with hematologic and non-hematologic malignancies. We report a case of asymptomatic CD4/CD8 double-positive T-LGLL. …”
Get full text

Carbonic anhydrase 2-derived drug-responsive domain regulates membrane-bound cytokine expression and function in engineered T cells by Mara C. Inniss, Sean G. Smith, Dan Jun Li, Benjamin Primack, Dexue Sun, Grace Y. Olinger, Kerri-Lynn Sheahan, Theresa Ross, Meghan Langley, Violet Young, Andres Alvarado, Shabnam Davoodi, Jiefei Geng, Michael Schebesta, Michelle L. Ols, Jeremy Tchaicha, Jan ter Meulen, Dhruv K. Sethi

“…Abstract Adoptive cell therapies (ACT) have shown reduced efficacy against solid tumor malignancies compared to hematologic malignancies, partly due to the immunosuppressive nature of the tumor microenvironment (TME). …”
Get full text

Tissue-specific roles of de novo DNA methyltransferases by Dániel Márton Tóth, Flóra Szeri, Mária Ashaber, Muhyiddeen Muazu, Lóránt Székvölgyi, Tamás Arányi

“…Additionally, somatic mutations cause common conditions such as osteoarthritis, osteoporosis, clonal hematopoiesis of indeterminate potential (CHIP), hematologic malignancies, and cancer. While DNMTs have been extensively studied in vitro, in early development and in disease, their detailed physiologic roles remain less understood as in vivo investigations are hindered by the embryonic or perinatal lethality of the knockout mice. …”
Get full text

Early Radiologic Diagnosis of Pulmonary Infection in Febrile Neutropenic Patients: A Comparison of Serial Chest Radiography and Single CT Chest by Wanaporn Burivong, Thanatorn Sricharoen, Apichart Thachang, Sunsiree Soodchuen, Panitpong Maroongroge, Vichit Leelasithorn

“…This study included 78 patients with hematologic malignancies who developed 107 episodes of febrile neutropenia from January 2012 to October 2017 and had a chest film performed within the first seven days. …”
Get full text

Knockout IL4I1 affects macrophages to improve poor efficacy of CD19 CAR-T combined with PD-1 inhibitor in relapsed/refractory diffuse large B-cell lymphoma by Rui Zhang, Yi Zhang, Hairong Xiao, Qingxi Liu, Mingfeng Zhao

“…Abstract Chimeric antigen receptor (CAR) T-cell therapy plays a critical role in the treatment of B-cell hematologic malignancies. The combination of PD-1 inhibitors and CAR-T has shown encouraging results in treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). …”
Get full text